Insights7 min read
Unannounced FDA inspections make “always on” the only strategy
FDA’s May 2025 expansion of surprise foreign inspections — built on India/China pilots — meets our dashboard data: VAI-heavy years and a corridor that lives on continuous readiness.
For years, foreign plants often got advance notice before FDA walked in. That buffer is shrinking fast. Combine the agency’s May 2025 policy shift with India dashboard volumes and corridor VAI density, and the operating assumption becomes: the floor must be inspection-ready every shift — not every announced visit.
What FDA announced
On May 6, 2025, FDA said it would expand unannounced inspections at foreign facilities making foods, essential medicines, and other medical products for the US. The move builds on Office of Inspection and Investigations pilots in India and China. Commissioner Makary framed it as ending a “double standard” versus domestic surprise inspections. Firms that delay, deny, or limit an unannounced drug inspection can face regulatory action.
Industry coverage (Express Pharma, NSF summaries of the bulletin) notes the India pilot alone had already run scores of unannounced visits by mid-2024 — proof the model was not theoretical before the nationwide expansion.
What our dashboard still shows
- FY2024–25 India drug inspections matched the 2019 peak (275 and 290)
- VAI remains enormous — the “fix voluntarily” bucket, not a clean bill
- Hyderabad corridor: 68 VAIs since FY2024 alone across the warning-shot cohort
- 51% of India OAI drug inspections drew a Warning Letter at the same FEI within 18 months
What the press is reporting in 2026
Moneycontrol (Apr 2026) reported fewer Official Action Indicated outcomes at Indian drug sites in FY26 even as surprise inspections expanded — with VAI rising as inspectors still find fixable deficiencies. Business Standard pieces through late 2025 / early 2026 similarly describe cleaner headline OAI rates for larger Indian firms under sharper, less predictable scrutiny. That is not a contradiction of our tables: calendar-year inspection counts can fall while fiscal peaks stay high, and “fewer OAIs” can coexist with more VAI and always-on readiness pressure.
IPA and industry voices quoted in Business Standard put it plainly: you cannot be “inspection-ready for Tuesday.” Under surprise foreign inspections, readiness is a 24×7 operating system.
Why cameras show up in this story
Unannounced visits remove the weekend SOP drill. Continuous physical behaviors — gowning, interventions, cleaning, who is actually watching the fill — are exactly what our citation map flags as camera-witnessable, and what Eugia’s public 483 text shows FDA reviewing on tape. Always-on inspection posture and always-on floor evidence are the same design problem.
Sources (web + data)
- FDA — Expanded use of unannounced inspections at foreign facilities (6 May 2025)
- Express Pharma — What surprise foreign inspections mean for India
- Moneycontrol — Fewer OAIs in FY26 as surprise inspections expand (15 Apr 2026)
- Business Standard — Cleaner Indian outcomes under harsher scrutiny (Feb 2026)
- GroundStatus — India inspection wave (dashboard)